Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

B-RAF is the most frequently mutated protein kinase in human cancers.1 The finding that oncogenic mutations in BRAF are common in melanoma2 followed by the demonstration that these tumors are dependent on the RAF/MEK/ERK pathway3 offered hope that inhibition of B-RAF kinase activity could benefit me...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bollag, Gideon, Hirth, Peter, Tsai, James, Zhang, Jiazhong, Ibrahim, Prabha N., Cho, Hanna, Spevak, Wayne, Zhang, Chao, Zhang, Ying, Habets, Gaston, Burton, Elizabeth A., Wong, Bernice, Tsang, Garson, West, Brian L., Powell, Ben, Shellooe, Rafe, Marimuthu, Adhirai, Nguyen, Hoa, Zhang, Kam Y. J., Artis, Dean R., Schlessinger, Joseph, Su, Fei, Higgins, Brian, Iyer, Raman, D'Andrea, Kurt, Koehler, Astrid, Stumm, Michael, Lin, Paul S., Lee, Richard J., Grippo, Joseph, Puzanov, Igor, Kim, Kevin B., Ribas, Antoni, McArthur, Grant A., Sosman, Jeffrey A., Chapman, Paul B., Flaherty, Keith T., Xu, Xiaowei, Nathanson, Katherine L., Nolop, Keith
Formato: Artigo
Idioma:Inglês
Publicado em: 2010
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2948082/
https://ncbi.nlm.nih.gov/pubmed/20823850
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature09454
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados